1
|
Lippiello P, Bencherif M, Hauser T, Jordan K, Letchworth S, Mazurov A. Nicotinic receptors as targets for therapeutic discovery. Expert Opin Drug Discov 2015; 2:1185-203. [PMID: 23496128 DOI: 10.1517/17460441.2.9.1185] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Nicotinic acetylcholine receptors (nAChRs) represent a class of therapeutic targets with the potential to impact numerous diseases and disorders where significant unmet medical needs remain. The latter include cognitive and neurodegenerative diseases; psychotic disorders, such as schizophrenia; acute nociceptive, neuropathic and inflammatory pain; affective disorders, such as depression and inflammation, where nAChR subtypes modulate key cellular pathways involved in anti-inflammatory processes as well as cell survival. Our increased understanding of the heterogeneity of nAChR targets is defining the relationship of biologic effects to specific receptor subtypes, which in turn, will allow further refinement of desired therapeutic activities. Both preclinical and clinical evidence support the notion that novel compounds targeting specific nAChR subtypes will offer increased potency and efficacy, longer lasting effects, fewer side effects and a more rapid onset of action and less dependence, compared with existing therapies. Clinical proof-of-concept is rapidly emerging and will solidify the position of this new therapeutic approach.
Collapse
Affiliation(s)
- Pm Lippiello
- Targacept, Inc., 200 East 1st Street, Suite 300, Winston-Salem, NC 27101, USA +1 336 480 2100 ; +1 336 480 2107 ;
| | | | | | | | | | | |
Collapse
|
2
|
An experimental study on (131)I-CHIBA-1001: a radioligand for α7 nicotinic acetylcholine receptors. PLoS One 2013; 8:e70188. [PMID: 23936161 PMCID: PMC3728097 DOI: 10.1371/journal.pone.0070188] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 06/14/2013] [Indexed: 11/19/2022] Open
Abstract
Objective The α7 nicotinic acetylcholine receptors (nAChRs) play a vital role in the pathophysiology of neuropsychiatric diseases such as Alzheimer’s disease and depression. However, there is currently no suitable positron emission tomography (PET) or Single-Photon Emission Computed Tomography (SPECT) radioligands for imaging α7 nAChRs in brain. Here our aim is to radiosynthesize a novel SPECT radioligand 131I-CHIBA-1001 for whole body biodistribution study and in vivo imaging of α7 nAChRs in brain. Method 131I-CHIBA-1001 was radiosynthesized by chloramine-T method. Different conditions of reaction time and temperature were tested to get a better radiolabeling yield. Radiolabeling yield and radiochemical purities of 131I-CHIBA-1001 were analyzed by thin layer chromatography (TLC) and high-performance liquid chromatography (HPLC) system. Whole body biodistribution study was performed at different time points post injection of 131I-CHIBA-1001 in KM mice. Monkey subject was used for in vivo SPECT imaging in brain. Result The radiolabeling yield of 131I-CHIBA-1001 reached 96% within 1.5∼2.0 h at 90∼95°C. The radiochemical purity reached more than 99% after HPLC purification. 131I-CHIBA-1001 was highly stable in saline and fresh human serum in room temperature and 37°C separately. The biodistribution data of brain at 15, 30, and 60 min were 11.05±1.04%ID/g, 8.8±0.04%ID/g and 6.28±1.13%ID/g, respectively. In experimental SPECT imaging, the distribution of radioactivity in the brain regions was paralleled with the distribution of α7 nAChRs in the monkey brain. Moreover, in the blocking SPECT imaging study, the selective α7 nAChR agonist SSR180711 blocked the radioactive uptake in the brain successfully. Conclusion The CHIBA-1001 can be successfully radiolabeled with 131I using the chloramine-T method. 131I-CHIBA-1001 can successfully accumulate in the monkey brain and image the α7 acetylcholine receptors. 131I-CHIBA-1001 can be a candidate for imagingα7 acetylcholine receptors, which will be of great value for the diagnosis and treatment of mental diseases.
Collapse
|
3
|
Ondachi P, Castro A, Luetje CW, Damaj MI, Mascarella SW, Navarro HA, Carroll FI. Synthesis and nicotinic acetylcholine receptor in vitro and in vivo pharmacological properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues of 2'-fluoro-3'-(4-nitrophenyl)deschloroepibatidine. J Med Chem 2012; 55:6512-22. [PMID: 22742586 DOI: 10.1021/jm300575y] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Herein, we report the synthesis and nicotinic acetylcholine receptor (nAChR) in vitro and in vivo pharmacological properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidines 5b-g, analogues of 3'-(4-nitrophenyl) compound 5a. All compounds had high affinity for α4β2-nAChR and low affinity for α7-nAChR. Initial electrophysiological studies showed that all analogues were antagonists at α4β2-, α3β4-, and α7-nAChRs. The 4-carbamoylphenyl analogue 5g was highly selective for α4β2-nAChR over α3β4- and α7-nAChRs. All the analogues were antagonists of nicotine-induced antinociception in the tail-flick test. Molecular modeling docking studies using the agonist-bound form of the X-ray crystal structure of the acetylcholine binding protein suggested several different binding modes for epibatidine, varenicline, and 5a-g. In particular, a unique binding mode for 5g was suggested by these docking simulations. The high binding affinity, in vitro efficacy, and selectivity of 5g for α4β2-nAChR combined with its nAChR functional antagonist properties suggest that 5g will be a valuable pharmacological tool for studying the nAChR and may have potential as a pharmacotherapy for addiction and other central nervous system disorders.
Collapse
Affiliation(s)
- Pauline Ondachi
- Center for Organic and Medicinal Chemistry, Research Triangle Institute, P.O. Box 12194, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | | | |
Collapse
|
4
|
Maier DL, Hill G, Ding M, Tuke D, Einstein E, Gurley D, Gordon JC, Bock MJ, Smith JS, Bialecki R, Eisman M, Elmore CS, Werkheiser JL. Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [3H]AZ11637326: Target localization, biodistribution and ligand occupancy in the rat brain. Neuropharmacology 2011; 61:161-71. [DOI: 10.1016/j.neuropharm.2011.03.024] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2010] [Revised: 03/03/2011] [Accepted: 03/30/2011] [Indexed: 11/15/2022]
|
5
|
Wu J, Toyohara J, Tanibuchi Y, Fujita Y, Zhang J, Chen H, Matsuo M, Wang RF, Hashimoto K. Pharmacological characterization of [125I]CHIBA-1006 binding, a new radioligand for α7 nicotinic acetylcholine receptors, to rat brain membranes. Brain Res 2010; 1360:130-7. [DOI: 10.1016/j.brainres.2010.08.095] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2010] [Revised: 08/27/2010] [Accepted: 08/27/2010] [Indexed: 11/26/2022]
|
6
|
In vitro binding characteristics of [3H]AZ11637326, a novel alpha7-selective neuronal nicotinic receptor agonist radioligand. Eur J Pharmacol 2010; 645:63-9. [PMID: 20674564 DOI: 10.1016/j.ejphar.2010.07.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Revised: 06/09/2010] [Accepted: 07/15/2010] [Indexed: 11/23/2022]
Abstract
AZ11637326 (5'-(2-fluoro[3,4,5(-3)H3]phenyl)-spiro[1-azabicyclo [2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine) is a potent partial agonist at the human alpha7 neuronal nicotinic receptor with sub-nanomolar affinity for the human and rat alpha7 [(125)I]alpha-bungarotoxin binding sites. In a search for novel agonist radioligands and imaging ligands for the alpha7 nicotinic receptor, [(3)H]AZ11637326 was synthesized and its in vitro membrane binding properties were characterized. [(3)H]AZ11637326 bound to halpha7-HEK membranes with high specificity (>95%), high affinity (230 pM) and a B(max) of 460 fmol/mg. The rank order of affinity of nicotinic standards determined with [(3)H]AZ11637326 strongly correlated with those determined using the classical alpha7 antagonist [(125)I]alpha-bungarotoxin, indicating that [(3)H]AZ11637326 bound to halpha7-HEK membranes with an alpha7 nicotinic-like pharmacology. The K(i) values for the standards were on average 2.3-fold lower affinity than determined using the prototypical alpha7 nicotinic antagonist [(125)I]alpha-bungarotoxin. Because [(3)H]AZ11637326 specific binding is rapid and reversible, the K(i) values determined using this ligand are more accurate estimates of affinity than those determined using the kinetically sluggish [(125)I]alpha-bungarotoxin. [(3)H]AZ11637326 also bound to a high affinity (510 pM), nicotine-sensitive site on rat hippocampal membranes with an average B(max) of 55 fmol/mg. With rat hippocampal membranes, the nicotine-sensitive fraction of total binding was sub-optimal for a radioligand (~50%), yet the potencies and rank order of the K(i) values for standards were consistent with an alpha7 nicotinic pharmacology. Overall, these studies indicate that [(3)H]AZ11637326 is a useful new in vitro probe of the alpha7 nicotinic receptor agonist site and support its potential utility for in vivo receptor occupancy studies.
Collapse
|
7
|
Abdrakhmanova GR, Blough BE, Nesloney C, Navarro HA, Damaj MI, Carroll FI. In vitro and in vivo characterization of a novel negative allosteric modulator of neuronal nAChRs. Neuropharmacology 2010; 59:511-7. [PMID: 20633568 DOI: 10.1016/j.neuropharm.2010.07.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2010] [Revised: 06/30/2010] [Accepted: 07/05/2010] [Indexed: 11/16/2022]
Abstract
In this study, we compared the in vitro and in vivo neuronal nicotinic acetylcholine receptor (nAChR) properties of 1,2,3,3a,4,8b-hexahydro-2-benzyl-6-N,N-dimethylamino-1-methylindeno[1,2,-b]pyrrole (HDMP, 4) to that of negative allosteric modulator (NAM), PCP. Patch-clamp experiments showed that HDMP exhibited an inhibitory functional activity at α7 nAChRs with an IC(50) of 0.07 μM, and was 357- and 414-fold less potent at α4β2 and α3β4 nAChRs, with IC(50)s of 25.1 and 29.0 μM, respectively. Control patch-clamp experiments showed that PCP inhibited α7, α4β2 and α3β4 nAChRs with IC(50)s of to 1.3, 29.0 and 6.4 μM, respectively. Further, HDMP did not exhibit any appreciable binding affinity to either α7 or α4β2 nAChRs, suggesting its action via a non-competitive mechanism at these neuronal nAChR subtypes. The in vivo study showed that HDMP was a potent antagonist of nicotine-induced analgesia in the tail-flick (AD(50)=0.008 mg/kg), but not in the hot-plate test. All together, our in vitro and in vivo data suggest that HDMP is a novel NAM of neuronal nAChRs with potent inhibitory activity at α7 nAChR subtype at concentrations ≤ 1μM that are not effective for α4β2 and α3β4 nAChRs.
Collapse
Affiliation(s)
- Galya R Abdrakhmanova
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, 1112 E. Clay Str., P.O. Box 980524, Richmond, VA 23298, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Dukat M, Wesołowska A, Alley G, Young S, Abdrakhmanova GR, Navarro HA, Young R, Glennon RA. MD-354 selectively antagonizes the antinociceptive effects of (-)nicotine in the mouse tail-flick assay. Psychopharmacology (Berl) 2010; 210:547-57. [PMID: 20431995 DOI: 10.1007/s00213-010-1857-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Accepted: 03/31/2010] [Indexed: 11/30/2022]
Abstract
RATIONALE (-)Nicotine produces antinociceptive effects in rodents. meta-Chlorophenylguanidine (MD-354), an analgesia-enhancing agent, binds at 5-HT(3) and alpha(2)-adrenoceptors and potentiates the antinociceptive effects of an "inactive" dose of clonidine. The present study examined the actions of MD-354 on (-)nicotine-induced antinociception. MATERIALS AND METHODS Mouse tail-flick and other assays were employed. RESULTS In the tail-flick assay, (-)nicotine (ED(50) = 1.66 mg/kg) but not MD-354 produced dose-related antinociceptive effects. Administered in combination with (-)nicotine (2.5 mg/kg), MD-354 (AD(50) = 3.4 mg/kg) did not potentiate, but effectively antagonized the antinociceptive actions of (-)nicotine. In a mouse hot-plate assay, MD-354 failed to modify (-)nicotine responses. In combination with a locomotor activity-suppressing dose of (-)nicotine, MD-354 (up to 17 mg/kg) failed to antagonize (-)nicotine-induced hypolocomotion. In a rat drug discrimination paradigm using (-)nicotine as training drug, MD-354 produced saline-appropriate responding; in combination with the training dose of (-)nicotine, MD-354 failed to antagonize the nicotine cue. CONCLUSIONS MD-354 selectively antagonizes the antinociceptive actions of (-)nicotine in the tail-flick, but not in the hot-plate assay, or either the motor effects, or discriminative stimulus effects of (-)nicotine. The most parsimonious explanation is that MD-354 might act as a negative allosteric modulator of alpha 7 nACh receptors, and radioligand binding and functional data are provided to support this conclusion.
Collapse
Affiliation(s)
- Małgorzata Dukat
- Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box 980540, Richmond, VA 23298-0540, USA.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Ogawa M, Nishiyama S, Tsukada H, Hatano K, Fuchigami T, Yamaguchi H, Matsushima Y, Ito K, Magata Y. Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor α7 subtype. Nucl Med Biol 2010; 37:347-55. [DOI: 10.1016/j.nucmedbio.2009.11.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Revised: 11/06/2009] [Accepted: 11/25/2009] [Indexed: 12/01/2022]
|
10
|
Carroll FI, Ma W, Deng L, Navarro HA, Damaj MI, Martin BR. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists. JOURNAL OF NATURAL PRODUCTS 2010; 73:306-312. [PMID: 20038125 PMCID: PMC2846203 DOI: 10.1021/np9006124] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
In 1992, John Daly et al. reported the isolation and structure determination of epibatidine. Epibatidine's unique structure and its potent nicotinic agonist activity have had a tremendous impact on nicotine receptor research. This research has led to a better understanding of the nicotinic acetylcholine receptor (nAChR) pharmacophore and to epibatidine analogues with potential as pharmacotherapies for treating various CNS disorders. In this study, we report the synthesis, receptor binding ([(3)H]epibatidine and [(125)I]iodoMLA), and in vivo pharmacological properties (mouse tail flick, hot plate, hypothermia, and spontaneous activity) of a series of 3'-(substituted phenyl)epibatidine analogues (5a-m). Results from these studies have added to the understanding of the nAChR pharmacophore and led to nicotinic partial agonists that may have potential for smoking cessation. All the analogues had affinities for the alpha4beta2 nAChR similar to epibatidine (1). 3'-(3-Dimethylaminophenyl)epibatidine (5m) has a nicotinic partial agonist pharmacological profile similar to the smoking cessation drug varenicline. Other analogues are partial agonists with varying degrees of nicotinic functional agonist and antagonist activity. 3'-(3-Aminophenyl)epibatidine (5j) is a more potent functional agonist and antagonist in all tests than varenicline. 3'-(3-Fluorophenyl)epibatidine and 3'-(3-chlorophenyl)epibatidine (5c and 5e) are more potent than varenicline when tested as agonists in four pharmacological tests and antagonists when evaluated against nicotine in the analgesia hot-plate test.
Collapse
Affiliation(s)
- F Ivy Carroll
- Center for Organic and Medicinal Chemistry, Research Triangle Institute, North Carolina 27709, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Molecular imaging of α7 nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743. Eur J Nucl Med Mol Imaging 2009; 36:791-800. [DOI: 10.1007/s00259-008-1031-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2008] [Accepted: 11/21/2008] [Indexed: 01/05/2023]
|
12
|
Carroll FI, Robinson TP, Brieaddy LE, Atkinson RN, Mascarella SW, Damaj MI, Martin BR, Navarro HA. Synthesis and Nicotinic Acetylcholine Receptor Binding Properties of Bridged and Fused Ring Analogues of Epibatidine. J Med Chem 2007; 50:6383-91. [DOI: 10.1021/jm0704696] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- F. Ivy Carroll
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - T. Philip Robinson
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - Lawrence E. Brieaddy
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - Robert N. Atkinson
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - S. Wayne Mascarella
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - M. Imad Damaj
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - Billy R. Martin
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| | - Hernán A. Navarro
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298
| |
Collapse
|
13
|
Ivy Carroll F, Yokota Y, Ma W, Lee JR, Brieaddy LE, Burgess JP, Navarro HA, Damaj MI, Martin BR. Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs. Bioorg Med Chem 2007; 16:746-54. [PMID: 17964169 DOI: 10.1016/j.bmc.2007.10.027] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2007] [Revised: 10/01/2007] [Accepted: 10/10/2007] [Indexed: 10/22/2022]
Abstract
A series of 3'-(substituted phenyl)deschloroepibatidine analogs (5a-j) were synthesized. The alpha4beta2( *) and alpha7 nicotinic acetylcholine receptor (nAChR) binding properties and functional activity in the tail-flick, hot-plate, locomotor, and body temperature tests in mice of 5a-j were compared to those of the nAChR agonist, nicotine (1), epibatidine (4), and deschloroepibatidine (13), the partial agonist, varenicline (3), and the antagonist 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogs (7a-j). Unlike epibatidine and deschloroepibatidine, which are potent agonists in the tail-flick test, 5a-k show no or very low antinociceptive activity in the tail-flick or hot-plate test. However, they are potent antagonists in nicotine-induced antinociception in the tail-flick test, but weaker than the corresponding 2'-fluoro-3'-(substituted phenyl)deschloroepibatidines.
Collapse
Affiliation(s)
- F Ivy Carroll
- Organic and Medicinal Chemistry, Research Triangle Institute, PO Box 12194, Research Triangle Park, NC 27709, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Kobayashi S, Toyooka N, Zhou D, Tsuneki H, Wada T, Sasaoka T, Sakai H, Nemoto H, Garraffo HM, Spande TF, Daly JW. Flexible synthesis of poison-frog alkaloids of the 5,8-disubstituted indolizidine-class. II: Synthesis of (-)-209B, (-)-231C, (-)-233D, (-)-235B", (-)-221I, and an epimer of 193E and pharmacological effects at neuronal nicotinic acetylcholine receptors. Beilstein J Org Chem 2007; 3:30. [PMID: 21931443 PMCID: PMC2164953 DOI: 10.1186/1860-5397-3-30] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2007] [Accepted: 09/28/2007] [Indexed: 02/07/2023] Open
Abstract
Background The 5,8-disubstituted indolizidines constitute the largest class of poison-frog alkaloids. Some alkaloids have been shown to act as noncompetitive blockers at nicotinic acetylcholine receptors but the proposed structures and the biological activities of most of the 5,8-disubstituted indolizidines have not been determined because of limited supplies of the natural products. We have therefore conducted experiments to confirm proposed structures and determine biological activities using synthetic compounds. Recently, we reported that one of this class of alkaloids, (-)-235B', acts as a noncompetitive antagonist for α4β2 nicotinic receptors, and its sensitivity is comparable to that of the classical competitive antagonist for this receptor, dihydro-β-erythroidine. Results The enantioselective syntheses of (-)-209B, (-)-231C, (-)-233D, (-)-235B", (-)-221I, and what proved to be an epimer of natural 193E, starting from common chiral lactams have been achieved. When we performed electrophysiological recordings to examine the effects of the synthetic alkaloids on two major subtypes of nicotinic receptors (α4β2 and α7) expressed in Xenopus laevis oocytes, (-)-231C effectively blocked α4β2 receptor responses (IC50 value, 1.5 μM) with a 7.0-fold higher potency than for blockade of α7 receptor responses. In contrast, synthetic (-)-221I and (-)-epi-193E were more potent in blocking α7 receptor responses (IC50 value, 4.4 μM and 9.1 μM, respectively) than α4β2 receptor responses (5.3-fold and 2.0-fold, respectively). Conclusion We achieved the total synthesis of (-)-209B, (-)-231C, (-)-233D, (-)-235B", (-)-221I, and an epimer of 193E starting from common chiral lactams, and the absolute stereochemistry of natural (-)-233D was determined. Furthermore, the relative stereochemistry of (-)-231C and (-)-221I was also determined. The present asymmetric synthesis of the proposed structure for 193E revealed that the C-8 configuration of natural 193E should be revised. The selectivity for α4β2 and α7 nicotinic receptors differed markedly for the 5,8-disubstituted indolizidines tested, and thus it appears that the nature of the side chains in these indolizidines is crucial with regard to subtype-selectivity.
Collapse
Affiliation(s)
- Soushi Kobayashi
- Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani 2630, Toyama, 930-0194, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, Bifone A. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat. Neuropsychopharmacology 2006; 31:1690-703. [PMID: 16292320 DOI: 10.1038/sj.npp.1300955] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We have applied pharmacological magnetic resonance imaging (phMRI) methods to map the functional response to nicotine in drug-naïve rats. Nicotine (0.35 mg/kg intravenous (i.v.)) increased relative cerebral blood volume (rCBV) in cortical (including medial prefrontal, cingulate orbitofrontal, insular) and subcortical (including amygdala and dorsomedial hippocampus) structures. The pharmacological specificity of the effect was demonstrated by acute pretreatment with the nicotinic acetylcholine receptor (nAChR) ion-channel-blocking agent mecamylamine, which suppressed the rCBV response to nicotine. Control experiments with norepinephrine, a potent non-brain-penetrant vasopressor, at a dose that mimics the cardiovascular response induced by nicotine were performed to assess the potential confounding effects of peripheral blood pressure changes induced by nicotine. In an attempt to highlight the relative contribution of different nAChR subtypes to the observed activation pattern of nicotine, we also investigated the central phMRI response to an acute challenge with (R)-N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide) (cpdA, at 5, 10, 20, and 30 mg/kg i.v.) and 5-iodo-A-85380 (5IA, 5 mg/kg i.v.). CpdA is a selective agonist at homomeric alpha7 nAChRs, while 5IA features high in vivo affinity for the alpha4beta2* and other less-abundant beta2-containing nicotinic receptors. CpdA did not produce significant rCBV changes at any of the doses tested, whereas 5IA induced a pattern of activation very similar to that induced by nicotine. The lack of phMRI response to cpdA together with the high spatial overlap between the activation profile of nicotine and 5IA, suggest that the acute functional response to nicotine in drug-naïve rats is mediated by beta2-containing nAChR isoforms, presumably belonging to the alpha4beta2* subtype.
Collapse
Affiliation(s)
- Alessandro Gozzi
- Department of Neuroimaging, Centre of Excellence for Drug Discovery, Psychiatry, GlaxoSmithKline Medicines Research Centre, Verona, Italy.
| | | | | | | | | | | |
Collapse
|
16
|
Kulak JM, Carroll FI, Schneider JS. [125I]Iodomethyllycaconitine binds to α7 nicotinic acetylcholine receptors in monkey brain. Eur J Neurosci 2006; 23:2604-10. [PMID: 16817863 DOI: 10.1111/j.1460-9568.2006.04804.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
We examined the binding of the novel nicotinic acetylcholine receptor (nAChR) ligand [125I]iodomethyllycaconitine (iodoMLA) in the brains of M. cynomologous (macaque) monkeys. [125I]iodoMLA bound throughout the brain with the greatest density in the thalamus and moderate intensity in the basal ganglia and cortical regions. The Kd and Bmax in whole brain tissue were similar whether 1 mM nicotine (Kd 33.25 +/- 15.17 nM, Bmax 5.80 +/- 1.06 fmol/mg) or 2 microM of the alpha7-selective antagonist alpha-bungarotoxin (Kd 46.12 +/- 18.45 nM, Bmax 6.30 +/- 1.06 fmol/mg) was used for nonspecific binding. The subtype-selectivity of this ligand was further studied with competition binding studies using nicotine, alpha-bungarotoxin and noniodinated MLA. Each ligand completely inhibited [125I]iodoMLA binding throughout the monkey brain, with Ki values of 2.23 +/- 0.85 microM for nicotine, 2.72 +/- 1.71 nM for alpha-bungarotoxin and 1.83 +/- 0.35 nM MLA in the caudate and 2.03 +/- 1.14 microM, 2.65 +/- 0.86 nM and 3.32 +/- 0.71 nM, respectively, in the putamen. The alpha3beta2/alpha6*-selective antagonist alpha-conotoxin MII failed to inhibit [125I]iodoMLA binding in any brain region. In monkeys with cognitive deficits resulting from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration, [125I]iodoMLA binding was significantly increased in the striatum, similar to results previously observed for [125I]alpha-bungarotoxin. These results suggest that, under the present experimental conditions, [125I]iodoMLA was selective for alpha7-containing nAChRs and did not bind to alpha6-containing nAChRs. This radioligand may be a useful tool for selectively imaging alpha7-containing nAChRs in vivo.
Collapse
Affiliation(s)
- Jennifer M Kulak
- Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust St., 521 JAH, Philadelphia, PA 19107, USA.
| | | | | |
Collapse
|
17
|
Carroll FI, Ma W, Yokota Y, Lee JR, Brieaddy LE, Navarro HA, Damaj MI, Martin BR. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-substituted deschloroepibatidine analogues. Novel nicotinic antagonists. J Med Chem 2005; 48:1221-8. [PMID: 15715488 DOI: 10.1021/jm040160b] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of 3'-substituted deschloroepibatidine analogues (3a-g and 4) showed high affinity for alpha4beta2 binding and relatively weak affinity for alpha7 nAChRs. The 3'-ethynyl (3g) and 3'-fluoro (3a) analogues with K(i) values of 0.02 and 0.037 nM, respectively, were the most potent. Even though the alpha4beta2 binding affinity of several of the analogues were equal to that of epibatidine, all of the compounds were weak agonists in the antinociceptive, hypothermia, and spontaneous activity test in mice. In contrast, all of the compounds were functional antagonists of nicotine-induced antinociception. In general, compounds 3a-g and 4 were more potent in the tail-flick assay than the hot-plate test. For example, the 3'-fluoro analogue 3a and the N-methyl-3'-iodo analogue 4 showed AD(50) values of 0.07 and 0.04 microg/kg, respectively, in the tail flick test and only 35 and 0% inhibition at 20 and 10 microg/kg in the hot-plate assay, respectively. These results suggest that these compounds will be highly useful for identifying which specific receptor subtypes are involved in each of nicotine's pharmacological effects. The high affinity of the N-methyl-3'-iodo analogue 4 combined with its weak agonist and potent antagonist activity suggests that carbon-11 and iodine-123 analogues may be useful as PET and SPECT ligands, respectively, for studying nAChRs in vivo.
Collapse
Affiliation(s)
- F Ivy Carroll
- Chemistry and Life Sciences, Research Triangle Institute, P. O. Box 12194, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Carroll FI, Ware R, Brieaddy LE, Navarro HA, Damaj MI, Martin BR. Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2‘-Fluoro-3‘-(substituted phenyl)deschloroepibatidine Analogues. Novel Nicotinic Antagonist. J Med Chem 2004; 47:4588-94. [PMID: 15317468 DOI: 10.1021/jm040078g] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues (5a-k) showed high affinity for alpha4beta2 binding with no affinity at alpha7 nAChRs. The most potent compound was 2'-fluoro-3'-(4-nitrophenyl)deschloroepibatidine (5g) which possessed a Ki value of 0.009 nM. Surprisingly, none of the compounds showed agonist effects in pain tests and body temperature changes in mice even when tested at 10-15 mg/kg with the exception of 5b, which showed only very weak agonist effects. In contrast, all the compounds were potent functional antagonists of nicotine-induced antinociception. Interestingly, the 3'-substituted phenyl analogues 5b-k were 10-870-fold more effective as antagonists in the tail-flick test versus the hot-plate procedure. They failed to antagonize nicotine-induced hypothermia. The 4-chlorophenyl analogue (5e) (AD50 = 0.0003 in the tail-flick test) was the most potent and selective analogue. These results suggest that these compounds will be highly useful for identifying which specific receptor subtypes are involved in each of nicotine's pharmacological effects. These compounds also deserve consideration as potential pharmacotherapies for treatment of smoking cessation.
Collapse
Affiliation(s)
- F Ivy Carroll
- Chemistry and Life Sciences, Research Triangle Institute, P.O. Box 12194, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | |
Collapse
|
19
|
Glennon RA. 2. Medicinal chemistry of alpha4beta2 nicotinic cholinergic receptor ligands. PROGRESS IN MEDICINAL CHEMISTRY 2004; 42:55-123. [PMID: 15003719 DOI: 10.1016/s0079-6468(04)42002-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- Richard A Glennon
- Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box 581 MCV Station, Richmond, VA 23298, USA
| |
Collapse
|